XBP1, CD138 (Syndecan-1), CS1 (SLAMF7)

Class

Peptide vaccine (multi-peptide, adjuvanted with poly-ICLC/Montanide)

Pathway

Antigen-specific cytotoxic T-lymphocyte induction against plasma-cell antigens

Notes

original target text: XBP1, CD138 (Syndecan-1), CS1 (SLAMF7) -- multi-peptide epitopes

This mechanism describes a therapeutic cancer vaccine designed to teach the immune system to recognize and destroy malignant plasma cells, the cell type responsible for multiple myeloma. Rather than targeting a single molecule, the vaccine combines short protein fragments (peptides) derived from three antigens characteristic of plasma cells: XBP1, a transcription factor essential for antibody production; CD138 (Syndecan-1), a surface proteoglycan used clinically as a plasma-cell marker; and CS1 (SLAMF7), a surface glycoprotein involved in cell adhesion and signaling. These peptides are presented to the immune system alongside adjuvants that stimulate innate immune activation and prolong antigen exposure, prompting the body to generate cytotoxic T lymphocytes (killer T cells) capable of recognizing and eliminating cells displaying these antigens. Using peptides from three distinct targets rather than one broadens the immune response and reduces the chance that malignant cells escape by simply losing or downregulating a single marker. This general strategy, antigen-specific active immunotherapy, is relevant across plasma cell disorders, including precursor states that precede overt malignancy, where the goal is to intercept disease progression by harnessing the patient's own adaptive immune system rather than relying solely on cytotoxic or targeted drugs.